PMID- 33754228 OWN - NLM STAT- MEDLINE DCOM- 20210915 LR - 20220716 IS - 1970-9366 (Electronic) IS - 1828-0447 (Print) IS - 1828-0447 (Linking) VI - 16 IP - 3 DP - 2021 Apr TI - Health outcomes in COPD smokers using heated tobacco products: a 3-year follow-up. PG - 687-696 LID - 10.1007/s11739-021-02674-3 [doi] AB - Given that many patients with chronic obstructive pulmonary disease (COPD) smoke despite their symptoms, it is important to understand the long-term health impact of cigarette substitution with heated tobacco products (HTPs). We monitored health parameters for 3 years in COPD patients who substantially attenuated or ceased cigarette consumption after switching to HTPs. Changes in daily cigarette smoking, annualized disease exacerbations, lung function indices, patient-reported outcomes (CAT scores) and 6-minute walk distance (6MWD) from baseline were measured in COPD patients using HTPs at 12, 24 and 36 months. These were compared to a group of age- and sex-matched COPD patients who continued smoking. Complete data sets were available for 38 patients (19 in each group). Subjects using HTPs had a substantial decrease in annualized COPD exacerbations within the group mean (+/- SD) from 2.1 (+/- 0.9) at baseline to 1.4 (+/- 0.8), 1.2 (+/- 0.8) and 1.3 (+/- 0.8) at 12-, 24- and 36-month follow-up (p < 0.05 for all visits). In addition, substantial and clinically significant improvements in CAT scores and 6MWD were identified at all three time points in the HTP cohort. No significant changes were observed in COPD patients who continued smoking. This study is the first to describe the long-term health effects of HTP use in COPD patients. Consistent improvements in respiratory symptoms, exercise tolerance, quality of life, and rate of disease exacerbations were observed in patients with COPD who abstained from smoking or substantially reduced their cigarette consumption by switching to HTP use. FAU - Polosa, Riccardo AU - Polosa R AUID- ORCID: 0000-0002-8450-5721 AD - Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. polosa@unict.it. AD - Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital "Policlinico-V. Emanuele", University of Catania, Catania, Italy. polosa@unict.it. AD - Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), Universita di Catania, Catania, Italy. polosa@unict.it. AD - UOC Medicina Interna e Urgenza, AOU "Policlinico-V. Emanuele-San Marco", Via S. Sofia, 78-Ed. 4, p. 2, Stanza 78, 95100, Catania, Italy. polosa@unict.it. FAU - Morjaria, Jaymin B AU - Morjaria JB AD - Department of Respiratory Medicine, Royal Brompton and Harefield Hospital Foundation Trust, Harefield Hospital, Harefield, UK. FAU - Prosperini, Umberto AU - Prosperini U AD - Hospital "San Vincenzo", Taormina, Italy. FAU - Busa, Barbara AU - Busa B AD - UOC Farmacia Ospedaliera, Hospital ARNAS Garibaldi, Catania, Italy. FAU - Pennisi, Alfio AU - Pennisi A AD - Department of Respiratory Medicine, Hospital Clinics "Musumeci-Gecas", Catania, Italy. FAU - Gussoni, Gualberto AU - Gussoni G AD - Department for Clinical Research "Centro Studi" FADOI (Scientific Society of Internal Medicine), Milan, Italy. FAU - Rust, Sonja AU - Rust S AD - Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), Universita di Catania, Catania, Italy. FAU - Maglia, Marilena AU - Maglia M AD - Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. AD - Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital "Policlinico-V. Emanuele", University of Catania, Catania, Italy. FAU - Caponnetto, Pasquale AU - Caponnetto P AD - Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy. AD - Centre for the Prevention and Treatment of Tobacco Addiction (CPCT), Teaching Hospital "Policlinico-V. Emanuele", University of Catania, Catania, Italy. AD - Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), Universita di Catania, Catania, Italy. LA - eng GR - 21040100/Ateneo di Catania/ PT - Journal Article PT - Multicenter Study DEP - 20210323 PL - Italy TA - Intern Emerg Med JT - Internal and emergency medicine JID - 101263418 SB - IM CIN - Intern Emerg Med. 2021 Apr;16(3):545-547. PMID: 33765300 CIN - Intern Emerg Med. 2021 Nov;16(8):2331-2333. PMID: 33983473 EIN - Intern Emerg Med. 2022 Sep;17(6):1849. PMID: 35771359 MH - Aged MH - Disease Progression MH - *Electronic Nicotine Delivery Systems MH - Female MH - Follow-Up Studies MH - Humans MH - Italy MH - Male MH - Middle Aged MH - Patient Reported Outcome Measures MH - Pulmonary Disease, Chronic Obstructive/*physiopathology MH - Respiratory Function Tests MH - *Smokers MH - Walk Test PMC - PMC8049911 OTO - NOTNLM OT - COPD OT - Glo OT - Heated tobacco products OT - IQOS OT - Smoking cessation OT - Tobacco harm reduction COIS- RP is a full-time employee of the University of Catania, Italy, and Medical Director of the Institute for Internal Medicine and Clinical Immunology at the same University. In relation to his work in the area of tobacco control and respiratory diseases, RP has received lecture fees and research funding from Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Therapeutics, and Forest Laboratories. He has also served as a consultant for Pfizer, Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, Boehringer Ingelheim, Novartis, Duska Therapeutics, ECITA (Electronic Cigarette Industry Trade Association, in the UK), Arbi Group Srl., and Health Diplomats. RP has served on the Medical and Scientific Advisory Board (MSAB) of Cordex Pharma, Inc., CV Therapeutics, Duska Therapeutics Inc, Pfizer, and PharmaCielo. Lecture fees from a number of European EC industry and trade associations (including FIVAPE in France and FIESEL in Italy) were directly donated to vaper advocacy no-profit organizations. RP is also the founder of (1) the Center for Tobacco Prevention and treatment (CPCT) at the University of Catania and (2) the Center of Excellence for the acceleration of Harm Reduction (CoEHAR) at the same University, which has received support from Foundation for a Smoke-Free World to conduct eight independent investigator-initiated research projects on harm reduction. RP is also currently involved in the following pro bono activities: scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti-Smoking League), the Consumer Advocates for Smoke-free Alternatives (CASAA) and the International Network of Nicotine Consumers Organizations (INNCO); Chair of the European Technical Committee for standardization on "Requirements and test methods for emissions of electronic cigarettes" (CEN/TC 437; WG4). JBM has received honoraria for speaking and financial support to attend meetings/advisory boards from Wyeth, Chiesi, Pfizer, MSD, Boehringer Ingelheim, Teva, GSK/Allen & Hanburys, Napp, Almirall, AstraZeneca, Trudell, Cook Medical, Medela AG and Novartis. He has been an expert witness for a solicitor company acting for BATSA and all proceeds of the work were donated to a number of charities. All other authors have no relevant conflict of interest to declare in relation to this study. EDAT- 2021/03/24 06:00 MHDA- 2021/09/16 06:00 PMCR- 2021/03/23 CRDT- 2021/03/23 07:01 PHST- 2020/12/12 00:00 [received] PHST- 2021/02/13 00:00 [accepted] PHST- 2021/03/24 06:00 [pubmed] PHST- 2021/09/16 06:00 [medline] PHST- 2021/03/23 07:01 [entrez] PHST- 2021/03/23 00:00 [pmc-release] AID - 10.1007/s11739-021-02674-3 [pii] AID - 2674 [pii] AID - 10.1007/s11739-021-02674-3 [doi] PST - ppublish SO - Intern Emerg Med. 2021 Apr;16(3):687-696. doi: 10.1007/s11739-021-02674-3. Epub 2021 Mar 23.